| Autor: |
Neilan, Tomas G., Jassal, Davinder S., Scully, Michael F., Chen, Gang, Deflandre, Catherine, McAllister, Hester, Kay, Elaine, Austin, Sandra C., Halpern, Elkan F., Harmey, Judy H., Fitzgerald, Desmond J. |
| Zdroj: |
European Heart Journal; May2006, Vol. 27 Issue 10, p1251-1256, 6p |
| Abstrakt: |
Aims The use of doxorubicin (DOX) as a chemotherapeutic agent is limited by cardiac injury. Iloprost, a stable synthetic analogue of prostacyclin, has previously been shown to protect against DOX-induced cardiomyocyte injury in vitro. Here, we addressed whether iloprost is cardioprotective in vivo and whether it compromises the anti-tumour efficacy of DOX. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
